<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://142-54-23-223.fusionmedialtd.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Wed, 15 Jul 2026 08:45:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://142-54-23-223.fusionmedialtd.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>Form  144        ANAPTYSBIO, INC                        Filed by: Ware J. Anthony</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+Ware+J.+Anthony/26762585.html</link>
   <description>si-local-file:///var/storage/secattach/20260713/26762585.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+Ware+J.+Anthony/26762585.html</guid>
   <pubDate>Mon, 13 Jul 2026 16:12:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03531986</category>
   	  </item>
  <item>
   <title>Form  144        ANAPTYSBIO, INC                        Filed by: Ware J. Anthony</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+Ware+J.+Anthony/26762585.html</link>
   <description>si-local-file:///var/storage/secattach/20260713/26762585.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+Ware+J.+Anthony/26762585.html</guid>
   <pubDate>Mon, 13 Jul 2026 16:12:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03531986</category>
   	  </item>
  <item>
   <title>Form  144        ANAPTYSBIO, INC                        Filed by: Ware J. Anthony</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+Ware+J.+Anthony/26713478.html</link>
   <description>si-local-file:///var/storage/secattach/20260630/26713478.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+Ware+J.+Anthony/26713478.html</guid>
   <pubDate>Tue, 30 Jun 2026 16:04:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03531986</category>
   	  </item>
  <item>
   <title>Form  144        ANAPTYSBIO, INC                        Filed by: Ware J. Anthony</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+Ware+J.+Anthony/26713478.html</link>
   <description>si-local-file:///var/storage/secattach/20260630/26713478.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+Ware+J.+Anthony/26713478.html</guid>
   <pubDate>Tue, 30 Jun 2026 16:04:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03531986</category>
   	  </item>
  <item>
   <title>Form  144        ANAPTYSBIO, INC                        Filed by: MULROY DENNIS</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+MULROY+DENNIS/26706641.html</link>
   <description>si-local-file:///var/storage/secattach/20260629/26706641.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+MULROY+DENNIS/26706641.html</guid>
   <pubDate>Mon, 29 Jun 2026 16:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03531986</category>
   	  </item>
  <item>
   <title>Form  144        ANAPTYSBIO, INC                        Filed by: MULROY DENNIS</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+MULROY+DENNIS/26706641.html</link>
   <description>si-local-file:///var/storage/secattach/20260629/26706641.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++ANAPTYSBIO%2C+INC++++++++++++++++++++++++Filed+by%3A+MULROY+DENNIS/26706641.html</guid>
   <pubDate>Mon, 29 Jun 2026 16:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03531986</category>
   	  </item>
  <item>
   <title>Form  ARS        ANAPTYSBIO, INC           For: Dec 31</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++ANAPTYSBIO%2C+INC+++++++++++For%3A+Dec+31/26706504.html</link>
   <description>si-local-file:///var/storage/secattach/20260629/26706504.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++ANAPTYSBIO%2C+INC+++++++++++For%3A+Dec+31/26706504.html</guid>
   <pubDate>Mon, 29 Jun 2026 16:09:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03531986</category>
   	  </item>
  <item>
   <title>Form  ARS        ANAPTYSBIO, INC           For: Dec 31</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++ANAPTYSBIO%2C+INC+++++++++++For%3A+Dec+31/26706504.html</link>
   <description>si-local-file:///var/storage/secattach/20260629/26706504.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++ANAPTYSBIO%2C+INC+++++++++++For%3A+Dec+31/26706504.html</guid>
   <pubDate>Mon, 29 Jun 2026 16:09:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03531986</category>
   	  </item>
  <item>
   <title>Form  DEFA14A    ANAPTYSBIO, INC                      </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ANAPTYSBIO%2C+INC++++++++++++++++++++++/26706473.html</link>
   <description>si-local-file:///var/storage/secattach/20260629/26706473.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ANAPTYSBIO%2C+INC++++++++++++++++++++++/26706473.html</guid>
   <pubDate>Mon, 29 Jun 2026 16:07:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03531986</category>
   	  </item>
  <item>
   <title>Form  DEFA14A    ANAPTYSBIO, INC                      </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ANAPTYSBIO%2C+INC++++++++++++++++++++++/26706473.html</link>
   <description>si-local-file:///var/storage/secattach/20260629/26706473.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ANAPTYSBIO%2C+INC++++++++++++++++++++++/26706473.html</guid>
   <pubDate>Mon, 29 Jun 2026 16:07:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03531986</category>
   	  </item>
  <item>
   <title>Form  DEF 14A    ANAPTYSBIO, INC           For: Jun 29</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++ANAPTYSBIO%2C+INC+++++++++++For%3A+Jun+29/26706404.html</link>
   <description>si-local-file:///var/storage/secattach/20260629/26706404.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++ANAPTYSBIO%2C+INC+++++++++++For%3A+Jun+29/26706404.html</guid>
   <pubDate>Mon, 29 Jun 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03531986</category>
   	  </item>
 </channel>
</rss>
